From an efficacy standpoint, the iGlarLixi® combination demonstrates superior HbA1c reduction compared to either monotherapy while concurrently mitigating key limitations of its components—namely, the weight gain associated with insulin and the risk of hypoglycemia, achieving an optimal therapeutic balance [75,76]. This evidence concerns the gene INS and Hypoglycemia.